Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CHKA | P35790 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | VEGFA | P15692 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077752 | 0.95 | CHKA (0.61) | HDAC1HDAC6MAPTMEN1KMT2A | |
| SCHEMBL20333113 | 0.95 | CHKA (0.61) | HDAC1HDAC6MAPTMEN1KMT2A | |
| SCHEMBL28400351 | 0.88 | HDAC1 (0.51) | HDAC1HDAC6MAPTMEN1KMT2A | |
| SCHEMBL24317392 | 0.88 | MAPK1 (0.57) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2619093 | 0.87 | KDM1A (0.54) | HDAC1HDAC6MAPTMEN1KMT2A | |
| SCHEMBL2514655 | 0.87 | VEGFA (0.54) | MAPTMEN1KMT2AGAAVEGFA | |
| SCHEMBL1481700 | 0.87 | GPR119 (0.55) | MAPTMEN1KMT2AVEGFAEGLN1 | |
| SCHEMBL4408599 | 0.86 | GPR119 (0.56) | MAPTMEN1KMT2AGAAVEGFA | |
| SCHEMBL1020384 | 0.85 | MEN1 (0.53) | HDAC1HDAC6MEN1KMT2AGAA | |
| SCHEMBL31752526 | 0.85 | DRD2 (0.56) | HDAC1HDAC6MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4722203-A1 | 3,4-DIHYDROPHTHALAZIN-1(2H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Academy of Military Medical Sciences (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024251080-A1 | 3,4-DIHYDROPHTHALAZIN-1(2H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2024-12-12 | — | — | WO | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116897-A1 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-04-11 | — | — | US | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016146220-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2016-09-22 | — | — | WO | disclosed |
| EP-3070084-A1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2016-09-21 | — | — | EP | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| EP-3016948-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | Università Degli Studi Di Milano - Bicocca (IT) | 2016-05-11 | — | — | EP | disclosed |
| WO-2015001024-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001024-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HDAC1 502/4885HDAC6 330/4885MAPT 2459/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HDAC1 502/4885HDAC6 330/4885MAPT 2459/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HDAC6 7/4885MAPT 33/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | HDAC1 2265/4885HDAC6 1511/4885MAPT 1672/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HDAC1 502/4885HDAC6 330/4885MAPT 2459/4885 |
| US-20240116897-A1 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | SIRT7, SIRT1, BRD7 | HDAC1 9/4885HDAC6 12/4885MAPT 957/4885 |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | ALK, ERBB2, ABL1 | HDAC1 496/4885HDAC6 422/4885MAPT 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.